Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), announce that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for $27.00 per share in cash. The total value implied by the Transaction at closing is approximately $1.9bn. At Chiesi, initiatives in this area are spearheaded by Chiesi Global Rare Diseases, the Group’s business unit focused on research, development and commercialization of therapies for rare and ultra‑rare conditions.
Read the full article: Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding Its Global Rare Disease Portfolio //
Source: https://www.businesswire.com/news/home/20260429263104/en/Chiesi-Group-to-Acquire-KalVista-Pharmaceuticals-Expanding-its-Global-Rare-Disease-Portfolio